Switch to:
Also traded in: Germany, Israel, Mexico

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 7/10

vs
industry
vs
history
Cash to Debt 1.31
OPK's Cash to Debt is ranked lower than
52% of the 780 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.55 vs. OPK: 1.31 )
Ranked among companies with meaningful Cash to Debt only.
OPK' s Cash to Debt Range Over the Past 10 Years
Min: 0.13  Med: 13.08 Max: No Debt
Current: 1.31
Equity to Asset 0.75
OPK's Equity to Asset is ranked higher than
71% of the 719 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.64 vs. OPK: 0.75 )
Ranked among companies with meaningful Equity to Asset only.
OPK' s Equity to Asset Range Over the Past 10 Years
Min: -0.41  Med: 0.67 Max: 0.96
Current: 0.75
-0.41
0.96
F-Score: 5
Z-Score: 4.29
M-Score: 0.53
WACC vs ROIC
20.00%
-0.15%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 5/10

vs
industry
vs
history
Operating margin (%) -2.52
OPK's Operating margin (%) is ranked lower than
76% of the 732 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 8.61 vs. OPK: -2.52 )
Ranked among companies with meaningful Operating margin (%) only.
OPK' s Operating margin (%) Range Over the Past 10 Years
Min: -31624.44  Med: -82.88 Max: -2.52
Current: -2.52
-31624.44
-2.52
Net-margin (%) -0.80
OPK's Net-margin (%) is ranked lower than
73% of the 733 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 5.95 vs. OPK: -0.80 )
Ranked among companies with meaningful Net-margin (%) only.
OPK' s Net-margin (%) Range Over the Past 10 Years
Min: -31688.9  Med: -118.52 Max: -0.8
Current: -0.8
-31688.9
-0.8
ROE (%) -0.49
OPK's ROE (%) is ranked lower than
70% of the 756 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.84 vs. OPK: -0.49 )
Ranked among companies with meaningful ROE (%) only.
OPK' s ROE (%) Range Over the Past 10 Years
Min: -3196.93  Med: -21.01 Max: -0.49
Current: -0.49
-3196.93
-0.49
ROA (%) -0.35
OPK's ROA (%) is ranked lower than
68% of the 787 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.58 vs. OPK: -0.35 )
Ranked among companies with meaningful ROA (%) only.
OPK' s ROA (%) Range Over the Past 10 Years
Min: -1352.71  Med: -13.92 Max: -0.35
Current: -0.35
-1352.71
-0.35
ROC (Joel Greenblatt) (%) -25.73
OPK's ROC (Joel Greenblatt) (%) is ranked lower than
77% of the 777 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 13.38 vs. OPK: -25.73 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
OPK' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: -130662.93  Med: -367.75 Max: -25.73
Current: -25.73
-130662.93
-25.73
Revenue Growth (3Y)(%) 85.10
OPK's Revenue Growth (3Y)(%) is ranked higher than
97% of the 601 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 5.40 vs. OPK: 85.10 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
OPK' s Revenue Growth (3Y)(%) Range Over the Past 10 Years
Min: 0  Med: -11.6 Max: 152
Current: 85.1
0
152
EBITDA Growth (3Y)(%) 27.70
OPK's EBITDA Growth (3Y)(%) is ranked higher than
78% of the 568 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 9.40 vs. OPK: 27.70 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
OPK' s EBITDA Growth (3Y)(%) Range Over the Past 10 Years
Min: -74.6  Med: 6.6 Max: 161.2
Current: 27.7
-74.6
161.2
EPS Growth (3Y)(%) -16.40
OPK's EPS Growth (3Y)(%) is ranked lower than
79% of the 530 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.50 vs. OPK: -16.40 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
OPK' s EPS Growth (3Y)(%) Range Over the Past 10 Years
Min: -69.4  Med: -1.6 Max: 152.4
Current: -16.4
-69.4
152.4
GuruFocus has detected 3 Warning Signs with OPKO Health Inc $OPK.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» OPK's 10-Y Financials

Financials (Next Earnings Date: 2017-02-28)


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow
Oprt. Cash Flow & Net Income

» Details

Guru Trades

Q1 2016

OPK Guru Trades in Q1 2016

Ken Fisher 37,867 sh (+0.11%)
Paul Tudor Jones Sold Out
George Soros Sold Out
Murray Stahl 67,206 sh (-15.60%)
Mario Gabelli 100,775 sh (-30.39%)
Joel Greenblatt 30,179 sh (-74.93%)
» More
Q2 2016

OPK Guru Trades in Q2 2016

Paul Tudor Jones 27,173 sh (New)
Joel Greenblatt 267,485 sh (+786.33%)
Ken Fisher 37,826 sh (-0.11%)
Murray Stahl 66,333 sh (-1.30%)
Mario Gabelli 97,050 sh (-3.70%)
» More
Q3 2016

OPK Guru Trades in Q3 2016

Jim Simons 1,412,757 sh (New)
John Burbank 12,234 sh (New)
George Soros 59,837 sh (New)
Joel Greenblatt 535,214 sh (+100.09%)
Paul Tudor Jones 36,248 sh (+33.40%)
Ken Fisher 38,229 sh (+1.07%)
Mario Gabelli 97,050 sh (unchged)
Murray Stahl 60,179 sh (-9.28%)
» More
Q4 2016

OPK Guru Trades in Q4 2016

Ken Fisher 39,229 sh (+2.62%)
» More
» Details

Insider Trades

Latest Guru Trades with OPK

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Specialty & Generic    NAICS: 325412    SIC: 2834
Compare:NYSE:MNK, NYSE:VRX, OTCPK:HYPMY, NYSE:TARO, OTCPK:HKMPF, NYSE:PTHN, NAS:NBIX, OTCPK:IPSEY, NYSE:CTLT, NAS:ENDP, NAS:HZNP, OTCPK:IZQVF, NAS:AKRX, NAS:MDCO, NYSE:RDY, NAS:IRWD, OTCPK:SFOSF, NAS:RDUS, NAS:PCRX, OTCPK:HLUYY » details
Traded in other countries:XCY.Germany, OPK.Israel, OPK.Mexico,
Opko Health Inc is a biopharmaceutical and diagnostics company. The Company is engaged in the research and development of pharmaceutical products and vaccines.

OPKO Health Inc was originally incorporated in Delaware in October 1991 under the name Cytoclonal Pharmaceutics, Inc. The Company is a multi-national biopharmaceutical and diagnostics company. It is developing various solutions to diagnose, treat and prevent various conditions, including point-of-care tests, laboratory developed tests, molecular diagnostics tests, and proprietary pharmaceuticals and vaccines. It owns established pharmaceutical platforms in Chile, Spain, Mexico and Uruguay. It also has established pharmaceutical operations in Brazil. The Company owns a specialty active pharmaceutical ingredients manufacturer in Israel. The Company currently manages its operations in two reportable segments, pharmaceutical and diagnostics. The pharmaceutical segment consists of two operating segments, its (i) pharmaceutical research and development segment which is focused on the research and development of pharmaceutical products and vaccines, and (ii) the pharmaceutical operations it acquired in Chile, Spain, Mexico, Israel, Spain, Uruguay and Brazil. The diagnostics segment consists of two operating segments, the Companys (i) pathology operations it acquired through the acquisition of OPKO Lab and (ii) point-of-care and molecular diagnostics operations. Its main products Rayaldy and Alpharen are in phase 3 clinical development. Its competitors include diagnostic companies, reference laboratories, molecular diagnostic firms, universities and research institutions. The testing, manufacture, distribution, advertising, and marketing of drug and diagnostic products and medical devices are subject to extensive regulation by federal, state, and local governmental authorities in the U.S., including the FDA, and by similar agencies in other countries.

Top Ranked Articles about OPKO Health Inc

Weekly CEO Buys Highlights Spotlight shines on OPKO and Guess?
According to GuruFocus’ Insider Data, these are the largest CEO buys during the past week. The overall trend of CEOs is illustrated in the chart below: Read more...
Top Insider Buys Highlight for Week of Jan. 6 Insiders bought shares at Opko Health and Resolute Energy
The largest insider buys this week were for OPKO Health Inc. (NASDAQ:OPK), Compass Diversified Holdings (NYSE:CODI), Acceleron Pharma Inc. (NASDAQ:XLRN) and Resolute Energy Corp. (NYSE:REN). Read more...
Weekly CEO Buys Highlight Insiders invest in Natus, OPKO, Mobile Mini, S&T Bancorp, Investors Real Estate
According to GuruFocus’ Insider Data, these are the largest CEO buys during the past week. The overall trend of purchases is illustrated in the chart below: Read more...
CEO Phillip Frost Buys OPKO Health Insider purchased 24,800 shares
Phillip Frost (Insider Trades), CEO, chairman and 10% owner of OPKO Health Inc. (NASDAQ:OPK), purchased 24,800 shares of the company on Oct. 10. The average price per share was $9.82, for a total transaction of $243,536. Read more...
Weekly CEO Buys: Abbott Laboratories, GE, OPKO Health Recent insider buys from company CEOs
According to GuruFocus Insider Data, these are the largest CEO buys during the past week. The overall trend of purchases is illustrated in the chart below: Read more...
Weekly CEO Buys: Ryman Hospitality, OPKO Health, Actuant Corp. Recent insider buys from company CEOs
According to GuruFocus Insider Data, these are the largest CEO buys during the past week. The overall trend of purchases is illustrated in the chart below: Read more...
Weekly CEO Buys Highlight Stock purchases from QEP Resources, OPKO Health and Korn/Ferry International CEOs
According to GuruFocus Insider Data, these were the largest CEO buys during the past week. The overall trend of CEO buys is illustrated in the chart below: Read more...
Insider Buys of More Than $100,000: Opko Health Chairman purchases 16,000 shares in company
Opko Health Inc. (NASDAQ:OPK) CEO, Chairman and 10% owner Phillip Frost M.D. et al bought 16,000 shares on June 14 at a price of $9.01 per share. The total transaction amount was $144,160. Read more...
Weekly CEO Buys Highlights Citigroup, Opko, JMP Group, Tuesday Morning, Calamos lead list, according to GuruFocus Insider Data
According to GuruFocus Insider Data, these are the largest CEO buys during the past week. The overall trend of CEOs is illustrated in the chart below: Read more...

Ratios

vs
industry
vs
history
P/B 2.25
OPK's P/B is ranked higher than
60% of the 751 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.84 vs. OPK: 2.25 )
Ranked among companies with meaningful P/B only.
OPK' s P/B Range Over the Past 10 Years
Min: 2.17  Med: 8.7 Max: 800
Current: 2.25
2.17
800
P/S 3.62
OPK's P/S is ranked lower than
58% of the 710 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.90 vs. OPK: 3.62 )
Ranked among companies with meaningful P/S only.
OPK' s P/S Range Over the Past 10 Years
Min: 3.58  Med: 32.63 Max: 158.13
Current: 3.62
3.58
158.13
EV-to-EBITDA 93.69
OPK's EV-to-EBITDA is ranked lower than
95% of the 562 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 17.15 vs. OPK: 93.69 )
Ranked among companies with meaningful EV-to-EBITDA only.
OPK' s EV-to-EBITDA Range Over the Past 10 Years
Min: -146.6  Med: -34.9 Max: 539.9
Current: 93.69
-146.6
539.9
Current Ratio 1.97
OPK's Current Ratio is ranked lower than
56% of the 770 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.34 vs. OPK: 1.97 )
Ranked among companies with meaningful Current Ratio only.
OPK' s Current Ratio Range Over the Past 10 Years
Min: 0.88  Med: 5.1 Max: 415
Current: 1.97
0.88
415
Quick Ratio 1.80
OPK's Quick Ratio is ranked higher than
52% of the 769 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.75 vs. OPK: 1.80 )
Ranked among companies with meaningful Quick Ratio only.
OPK' s Quick Ratio Range Over the Past 10 Years
Min: 0.48  Med: 4.68 Max: 415
Current: 1.8
0.48
415
Days Inventory 25.28
OPK's Days Inventory is ranked higher than
93% of the 682 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 114.25 vs. OPK: 25.28 )
Ranked among companies with meaningful Days Inventory only.
OPK' s Days Inventory Range Over the Past 10 Years
Min: 25.28  Med: 233.05 Max: 500.07
Current: 25.28
25.28
500.07
Days Sales Outstanding 66.84
OPK's Days Sales Outstanding is ranked higher than
58% of the 623 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 75.25 vs. OPK: 66.84 )
Ranked among companies with meaningful Days Sales Outstanding only.
OPK' s Days Sales Outstanding Range Over the Past 10 Years
Min: 38.86  Med: 163.64 Max: 727.85
Current: 66.84
38.86
727.85
Days Payable 35.89
OPK's Days Payable is ranked lower than
81% of the 569 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 71.88 vs. OPK: 35.89 )
Ranked among companies with meaningful Days Payable only.
OPK' s Days Payable Range Over the Past 10 Years
Min: 35.89  Med: 112.55 Max: 1499.3
Current: 35.89
35.89
1499.3

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -21.30
OPK's 3-Year Average Share Buyback Ratio is ranked lower than
82% of the 429 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: -4.40 vs. OPK: -21.30 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
OPK' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -146.3  Med: -14.4 Max: 0.4
Current: -21.3
-146.3
0.4

Valuation & Return

vs
industry
vs
history
Price/Projected FCF 2.84
OPK's Price/Projected FCF is ranked lower than
52% of the 317 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.72 vs. OPK: 2.84 )
Ranked among companies with meaningful Price/Projected FCF only.
OPK' s Price/Projected FCF Range Over the Past 10 Years
Min: 2.8  Med: 9.57 Max: 177.5
Current: 2.84
2.8
177.5
Price/Median PS Value 0.11
OPK's Price/Median PS Value is ranked higher than
98% of the 641 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.10 vs. OPK: 0.11 )
Ranked among companies with meaningful Price/Median PS Value only.
OPK' s Price/Median PS Value Range Over the Past 10 Years
Min: 0.11  Med: 1.28 Max: 30
Current: 0.11
0.11
30
Earnings Yield (Greenblatt) (%) -1.03
OPK's Earnings Yield (Greenblatt) (%) is ranked lower than
74% of the 760 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.20 vs. OPK: -1.03 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
OPK' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: -1.03  Med: 0.5 Max: 0.5
Current: -1.03
-1.03
0.5

More Statistics

Revenue (TTM) (Mil) $1,222
EPS (TTM) $ -0.02
Beta2.41
Short Percentage of Float22.28%
52-Week Range $7.12 - 12.15
Shares Outstanding (Mil)557.53

Analyst Estimate

Dec16 Dec17 Dec18 Dec19
Revenue (Mil $) 1,250 1,365 1,607 2,151
EPS ($) -0.08 -0.01 0.26 0.70
EPS w/o NRI ($) -0.08 -0.01 0.26 0.70
EPS Growth Rate
(3Y to 5Y Estimate)
15.00%
Dividends Per Share ($)
» More Articles for OPK

Headlines

Articles On GuruFocus.com
Weekly CEO Buys Highlight Jan 22 2017 
Weekly CEO Buys Highlights Jan 09 2017 
Top Insider Buys Highlight for Week of Jan. 6 Jan 07 2017 
Weekly CEO Buys Highlights Dec 06 2016 
Weekly CEO Buys Highlight Oct 31 2016 
Weekly CEO Buys Highlights Oct 24 2016 
Weekly CEO Buys Highlight Oct 17 2016 
CEO Phillip Frost Buys OPKO Health Oct 11 2016 
Weekly CEO Buys Highlight Oct 03 2016 
Weekly CEO Buys Highlights Sep 26 2016 

More From Other Websites
Opko Health Eyes Better 2017 After Disastrous 2016 Jan 16 2017
OPKO HEALTH, INC. Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits Jan 10 2017
Opko Health investee company launches into new partnership Jan 10 2017
OPKO Investee Zebra Biologics Announces Collaboration with AbbVie to Discover New Antibody... Jan 10 2017
OPKO Announces Initiation of Claros® 1 Clinical Trial for Total PSA Jan 09 2017
Weekly CEO Buys Highlights Jan 09 2017
Top Insider Buys Highlight for Week of Jan. 6 Jan 07 2017
OPKO Health to Present at the J.P. Morgan 35th Annual Healthcare Conference Jan 04 2017
OPKO Health, Inc. breached its 50 day moving average in a Bearish Manner : OPK-US : January 4, 2017 Jan 04 2017
OPKO HEALTH, INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits Jan 03 2017
OPKO Health, Inc. – Value Analysis (NASDAQ:OPK) : January 3, 2017 Jan 03 2017
The Buffett of Biotech's Portfolio Jan 03 2017
Opko Health's 18% Selloff Offers Buying Opportunity Jan 03 2017
OPKO Health (OPK) Reports Failure in hGH-CTP Phase 3 Jan 02 2017
OPKO Health, Inc. breached its 50 day moving average in a Bearish Manner : OPK-US : January 2, 2017 Jan 02 2017
US STOCKS-Wall St ends solid 2016 on dour note Dec 30 2016
[$$] OPKO Health Shares Slide as Injection Doesn't Top Placebo in Trial Dec 30 2016
OPKO Health Provides Update on hGH-CTP Clinical Programs Dec 30 2016
OPKO Health to be Added to the NASDAQ Biotechnology Index Dec 19 2016
OPKO Announces U.S. Launch of RAYALDEE™ Nov 23 2016
OPKO Health Reports Third Quarter Financial and Operating Results Nov 07 2016
OPKO to Announce Third Quarter Operating and Financial Results on November 7, 2016 Nov 03 2016
OPKO Health Enters Companion Animal Health Market Oct 27 2016
OPKO Health Appoints Dr. Benjamin Solomon as Managing Director of GeneDx Sep 27 2016
OPKO Health Appoints Jane Pine Wood as Chief Legal and Compliance Officer of BioReference... Sep 13 2016
OPKO Health Completes Acquisition of Transition Therapeutics Aug 31 2016
Transition Therapeutics Shareholders Approve Acquisition by OPKO Health Aug 26 2016
OPKO Health Responds to Law Firm Notice of Investigation Aug 23 2016
Cocrystal Pharma Announces Filing 2016 Second Quarter Financial Statements and Provides Company... Aug 10 2016
OPKO Health Reports Improved Financial and Operating Results Aug 08 2016
OPKO to Announce Second Quarter Operating and Financial Results on August 8, 2016 Aug 03 2016
OPKO Health to Acquire Transition Therapeutics Jun 30 2016
OPKO Health to Host Analyst & Investor Day in New York City on June 15 Jun 14 2016
OPKO Health Announces Move to NASDAQ Stock Market Jun 13 2016
OPKO to Discuss Draft Coverage Determinations for 4Kscore® Test at 2016 Jefferies Healthcare... Jun 07 2016
OPKO Health to Present at the 2016 Jefferies Healthcare Conference Jun 02 2016
OPKO Health Receives Proposed/Draft Medicare Local Coverage Determination for 4Kscore® Test May 27 2016
US STOCKS-Wall St slips as US productivity falls, bond rout eases Jun 04 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)